08:32 AM EST, 11/12/2025 (MT Newswires) -- Immatics ( IMTX ) said Wednesday that updated phase 1a dose escalation data from the two product candidates in its TCR Bispecifics pipeline showed favorable tolerability at the recommended phase 2 dose in patients with advanced metastatic solid tumors.

The IMA402 and IMA401 TCR Bispecifics also demonstrated deep and durable responses in heavily pre-treated, last-line patients with a range of solid tumors, the company said.

Immatics ( IMTX ) said it is advancing its IMA402 PRAME Bispecific into phase 1b dose expansion at two distinct doses to determine the final recommended phase 2 dose, focusing on melanoma and gynecologic cancers in 2026.

The company said it is also exploring IMA401 in combination with IMA402, starting with squamous non-small cell lung cancer.